NYSE - Nasdaq Real Time Price USD

Becton, Dickinson and Company (BDX)

Compare
238.91 +0.78 (+0.33%)
At close: October 28 at 4:00 PM EDT
238.70 -0.21 (-0.09%)
After hours: October 28 at 7:29 PM EDT
Loading Chart for BDX
DELL
  • Previous Close 238.13
  • Open 238.60
  • Bid 235.75 x 800
  • Ask 240.68 x 800
  • Day's Range 237.87 - 240.90
  • 52 Week Range 218.75 - 259.92
  • Volume 925,104
  • Avg. Volume 1,268,932
  • Market Cap (intraday) 69.748B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 47.78
  • EPS (TTM) 5.00
  • Earnings Date Nov 7, 2024
  • Forward Dividend & Yield 3.80 (1.60%)
  • Ex-Dividend Date Sep 9, 2024
  • 1y Target Est 278.61

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

www.bd.com

70,000

Full Time Employees

September 30

Fiscal Year Ends

Recent News: BDX

View More

Performance Overview: BDX

Trailing total returns as of 10/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BDX
0.83%
S&P 500
22.09%

1-Year Return

BDX
3.50%
S&P 500
41.44%

3-Year Return

BDX
4.48%
S&P 500
27.94%

5-Year Return

BDX
7.60%
S&P 500
92.67%

Compare To: BDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BDX

View More

Valuation Measures

Annual
As of 10/25/2024
  • Market Cap

    68.83B

  • Enterprise Value

    82.84B

  • Trailing P/E

    47.72

  • Forward P/E

    17.12

  • PEG Ratio (5yr expected)

    1.10

  • Price/Sales (ttm)

    3.50

  • Price/Book (mrq)

    2.66

  • Enterprise Value/Revenue

    4.18

  • Enterprise Value/EBITDA

    18.64

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.13%

  • Return on Assets (ttm)

    3.25%

  • Return on Equity (ttm)

    5.63%

  • Revenue (ttm)

    19.83B

  • Net Income Avi to Common (ttm)

    1.46B

  • Diluted EPS (ttm)

    5.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.31B

  • Total Debt/Equity (mrq)

    74.70%

  • Levered Free Cash Flow (ttm)

    4.43B

Research Analysis: BDX

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 4.99B
Earnings 487M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

240.00
278.61 Average
238.91 Current
324.12 High
 

Company Insights: BDX

Research Reports: BDX

View More
  • Large Cap US Pick List - October 2024

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

     
  • Large Cap US Pick List - September 2024

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

     
  • BD's Alaris Trajectory Is Solid, While China Remains a Headwind

    Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

    Rating
    Price Target
     
  • We see GLP-1 autoinjectors driving growth

    Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.

    Rating
    Price Target
     

People Also Watch